TrialBreast cancer (Tokyo, Japan)2021

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.

Junichi Kurebayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.